Baker Tilly Professional

Brian Restivo

MBA, CHFP

Director

+1 (380) 799 5057

Brian is a director with Baker Tilly’s healthcare practice. He brings more than 14 years of experience in governmental reimbursement for three large integrated health systems to the firm.

  • Responsible for the leadership and strategic vision of corporate reimbursement, charge analysis and net revenue, including three direct management level reports and 20 indirect reports
  • System lead for more than $250 million of federal COVID-19 funding, including CARES Act Provider Relief Funds, FEMA and Ohio Coronavirus Funds
  • Subject matter expert on Medicare and Medicaid cost reporting and governmental reimbursement matters
  • Responsible for providing oversight of the completion of eight year-end third party cost reports
  • Worked collaboratively with the Graduate Medical Education Office to optimize cap building scenarios, affiliation agreements and completing financial analysis of adding new residency programs
  • Interpreted and shared knowledge with hospital and system leadership on Medicare regulations for new teaching hospitals, critical access hospitals, sole community hospitals, urban hospitals and rural hospitals
  • Responsible for preparation or supervision of multiple exhibits of third party cost reports for nine hospitals
  • Created data warehouse to improve analyzing and reporting of data for the purposes of completing cost reports, audits, budgets and other third party governmental analysis
  • Redesigned Disproportionate Share (DSH) processes to improve efficiency and increase reimbursement
  • Healthcare Financial Management Association (HFMA)
  • Certified Healthcare Finance Professional (CHFP)

Location

Columbus, OH

Education

Master of Business Administration in quality management

Hofstra University

(Hempstead, New York)

Bachelor of Science in business management

York College of Pennsylvania

Brian's upcoming events

Webinar

doctor hand medical cross graphic

Medicare reimbursement updates for fiscal year 2025